Stocks · News reference
BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.
Read original at benzingaMorgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
Read original at benzingaRBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and lowers the price target from $22 to $21.
Read original at benzingaB. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $17 to $22.
Read original at benzingaFiled: 2026-08-17 AccNo: 0001193125-26-354051 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgarBTIG analyst Sam Eiber maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
Read original at benzinga